Cardio-oncology & otherCohort study
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma
- Retrospective cohort study
Authors' conclusion
AF is a frequent and high-risk complication among MM patients undergoing ASCT.
Study context
- Population
- Multiple myeloma patients undergoing autologous stem cell transplantation (2016–2022), without atrial fibrillation (AF) at baseline
- Participants
- 801 patients
- Outcome
- Incidence, predictors and prognostic implications of post-transplantation AF (ECG-confirmed AF after stem cell infusion)
Main finding
As reported in the abstract
Post-transplantation AF · median follow-up 36.2 months
Patients developing post-transplantation AF
70 (8.7%)
Cumulative incidence at 90 days
5.5%
Cumulative incidence at 3 years
9.0%
Median onset
13 days
Observational data: associations, not effects.
Further findings
Independent predictors of post-transplantation AF
| Comparison | HR (95% CI) | |
|---|---|---|
| Age >65 years | 1.88 (1.16–3.07) | |
| Prior paroxysmal AF | 6.19 (3.63–10.5) | |
| Obesity | 2.00 (1.10–3.63) | |
| Left atrial volume index >34 mL/m² · not significant after adjustment | 1.67 (0.99–2.80) | |
| Corrected QT interval >480 ms · not significant after adjustment | 1.69 (0.91–3.12) | |
| 0.050.21520Hazard ratio (log scale) |
Independent predictors of post-transplantation AF
- Among patients without prior AF, corrected QT interval >480 ms remained a significant predictor
Mortality associated with post-transplantation AF (multivariable)
- Higher risk for all-cause mortality
- 5-fold
- Higher risk for nonrelapse mortality
- 4.5-fold
Original publication
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma. JACC CardioOncol. doi:10.1016/j.jaccao.2025.12.008
Summarised from the published abstract; every number is checked against it